Historical Valuation
Arcturus Therapeutics Holdings Inc (ARCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.09 is considered Fairly compared with the five-year average of -8.03. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 3.93 to 11.04 according to relative valuation methord.
Relative Value
Fair Zone
3.93-11.04
Current Price：6.78
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Arcturus Therapeutics Holdings Inc (ARCT) has a current Price-to-Book (P/B) ratio of 0.76. Compared to its 3-year average P/B ratio of 2.17 , the current P/B ratio is approximately -65.14% higher. Relative to its 5-year average P/B ratio of 2.60, the current P/B ratio is about -70.88% higher. Arcturus Therapeutics Holdings Inc (ARCT) has a Forward Free Cash Flow (FCF) yield of approximately -33.03%. Compared to its 3-year average FCF yield of -4.69%, the current FCF yield is approximately 604.34% lower. Relative to its 5-year average FCF yield of -10.56% , the current FCF yield is about 212.68% lower.
P/B
Median3y
2.17
Median5y
2.60
FCF Yield
Median3y
-4.69
Median5y
-10.56
Competitors Valuation Multiple
AI Analysis for ARCT
The average P/S ratio for ARCT competitors is 1.82, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT.O) exhibits a P/S ratio of 4.09, which is 123.92% above the industry average. Given its robust revenue growth of -58.84%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ARCT
1Y
3Y
5Y
Market capitalization of ARCT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ARCT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ARCT currently overvalued or undervalued?
Arcturus Therapeutics Holdings Inc (ARCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.09 is considered Fairly compared with the five-year average of -8.03. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 3.93 to 11.04 according to relative valuation methord.
What is Arcturus Therapeutics Holdings Inc (ARCT) fair value?
ARCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 3.93 to 11.04 according to relative valuation methord.
How does ARCT's valuation metrics compare to the industry average?
The average P/S ratio for ARCT's competitors is 1.82, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT) exhibits a P/S ratio of 4.09, which is 123.92% above the industry average. Given its robust revenue growth of -58.84%, this premium appears unsustainable.
What is the current P/B ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Jan 10 2026?
As of Jan 10 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a P/B ratio of 0.76. This indicates that the market values ARCT at 0.76 times its book value.
What is the current FCF Yield for Arcturus Therapeutics Holdings Inc (ARCT) as of Jan 10 2026?
As of Jan 10 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a FCF Yield of -33.03%. This means that for every dollar of Arcturus Therapeutics Holdings Inc’s market capitalization, the company generates -33.03 cents in free cash flow.
What is the current Forward P/E ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Jan 10 2026?
As of Jan 10 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a Forward P/E ratio of -2.48. This means the market is willing to pay $-2.48 for every dollar of Arcturus Therapeutics Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Jan 10 2026?
As of Jan 10 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a Forward P/S ratio of 4.09. This means the market is valuing ARCT at $4.09 for every dollar of expected revenue over the next 12 months.